NVS: Novartis AG - ADR Company Profile & Statistics

About

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.

Info & Links

CEO

Vasant Narasimhan

Headquarters

LICHTSTRASSE 35
BASEL, V8 CH 4056, SWITZERLAND

Auditor

KPMG AG

Share holders

Employees

76,057

Novartis AG - ADR Statistics

Valuation Measures

Market Capitalization²

199.15B

Enterprise Value

215.85B

Enterprise Value/EBITDA(ttm)

13.03

Price to Earnings Ratio(ttm)

13.36

Price to Sales(ttm)

4.11

Price to Book(mrq)

4.63

Price to Cash(ytd)

8.85

Profitability

Gross Margin(ttm)

74.90%

Operating Margin(ttm)

30.55%

Profit Margin(ttm)

35.90%

Return on Equity(ttm)

34.80%

Return on Invested Capital(ttm)

18.78%

Return on Assets(ttm)

15.13%

Income Statement

Revenue(ttm)

49.94B

Revenue Per Share(ttm)

Gross Profit(ttm)

37.41B

EBITDA(ttm)³

16.56B

Net Income Available to Common(ttm)

17.60B

Diluted EPS(ttm)

8.61

Share Statistics

Beta (5Y Monthly)

0.56

52-Week Change

2.15%

S&P 500 52-Week Change

25.66%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

Dividend Yield

2.47%

Float⁴

2.04B

% Held by Insiders

0.01%

% Held by Institutions

13.12%

Balance Sheet

Total Cash(mrq)

14.02B

Total Cash Per Share(mrq)

Total Debt(mrq)

30.32B

Total Debt/Equity(mrq)

69.79%

Current Ratio(mrq)

1.11%

Quick Ratio(mrq)

0.90%

Book Value Per Share(mrq)

21.73

Cash Flow

Operating Cash Flow Per Share(ytd)

6.62

Free Cash Flow(ytd)

12.66B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

NVS

Novartis AG - ADR

Novartis AG - ADR Profile